Kailera Therapeutics, INC. (KLRA) — SEC Filings

Overview

Kailera Therapeutics, INC. (KLRA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 20, 2026: On April 16, 2026, Adam Koppel reported a change in beneficial ownership of securities for Kailera Therapeutics, Inc. The filing, a Form 4, was accepted by the SEC on April 20, 2026. Specific details regarding the nature of the transaction and the number of shares involved are not provided in this s

Sentiment Summary

Across 19 filings, the sentiment breakdown is: 19 neutral. The dominant filing sentiment for Kailera Therapeutics, INC. is neutral.

Filing Type Overview

Kailera Therapeutics, INC. (KLRA) has filed 10 3, 6 4, 1 EFFECT, 1 S-1MEF, 1 S-1/A with the SEC between Apr 2026.

Recent Filings (19)

• Kailera Therapeutics: Insider Ownership Change Reported — 4 · Apr 20, 2026 Risk: low
  On April 16, 2026, Adam Koppel reported a change in beneficial ownership of securities for Kailera Therapeutics, Inc. The filing, a Form 4, was accepted by the
• Bain Capital Entities Report Kailera Therapeutics Security Changes — 4 · Apr 20, 2026 Risk: medium
  On April 20, 2026, Bain Capital Life Sciences Investors, LLC, along with its related entities Bain Capital Life Sciences IV General Partner, LLC, Bain Capital L
• Kailera Therapeutics: Insider Ownership Change Reported — 4 · Apr 20, 2026 Risk: low
  On April 16, 2026, Andrew T. Kaplan, a reporting person associated with Kailera Therapeutics, Inc., reported a change in beneficial ownership of securities. The
• Kailera Therapeutics: Ownership Change Reported — 4 · Apr 20, 2026 Risk: low
  On April 16, 2026, Paul D. Burgess, a reporting person associated with Translate Bio, Inc., reported a change in beneficial ownership of securities related to K
• 4 Filing — 4 · Apr 20, 2026
• 4 Filing — 4 · Apr 20, 2026
• Kailera Therapeutics Registration Statement Effectiveness — EFFECT · Apr 17, 2026 Risk: low
  Kailera Therapeutics, Inc. filed an EFFECT form, indicating the effectiveness of a registration statement, on April 17, 2026. The filing, with SEC Accession No.
• Kailera Therapeutics Files Initial Ownership Statement — 3 · Apr 16, 2026 Risk: low
  On April 16, 2026, Kailera Therapeutics, Inc. (CIK: 0002096997) filed a Form 3, an initial statement of beneficial ownership of securities. The filing was made
• 3 Filing — 3 · Apr 16, 2026
• 3 Filing — 3 · Apr 16, 2026
• 3 Filing — 3 · Apr 16, 2026
• Kailera Therapeutics: Initial Ownership Filing — 3 · Apr 16, 2026 Risk: low
  On April 16, 2026, Christopher Hite filed an initial statement of beneficial ownership of securities (Form 3) for Kailera Therapeutics, Inc. The filing indicate
• Kailera Therapeutics Files Initial Ownership Statement — 3 · Apr 16, 2026 Risk: low
  On April 16, 2026, Kailera Therapeutics, Inc. filed an initial statement of beneficial ownership of securities (Form 3). The filing was made by Paula Cloghessy,
• 3 Filing — 3 · Apr 16, 2026
• Kailera Therapeutics: Initial Ownership Filing — 3 · Apr 16, 2026 Risk: low
  On April 16, 2026, Frank Clyburn (CIK 0001763963) filed an initial statement of beneficial ownership of securities (Form 3) for Kailera Therapeutics, Inc. (CIK
• 3 Filing — 3 · Apr 16, 2026
• Kailera Therapeutics Files S-1MEF for Additional Securities — S-1MEF · Apr 16, 2026 Risk: medium
  Kailera Therapeutics, Inc. filed an S-1MEF on April 16, 2026, to register additional securities under a prior Form S-1 registration. The filing indicates the co
• 3 Filing — 3 · Apr 16, 2026
• Kailera Therapeutics Files S-1/A Amendment — S-1/A · Apr 13, 2026 Risk: medium
  Kailera Therapeutics, Inc. filed an S-1/A amendment on April 13, 2026, to register securities. The filing includes various exhibits such as the company's charte

Related Companies

KLR

Frequently Asked Questions